CRYOPORT, INC. (CYRX) Gross Margin
- Gross margin · 12 months: Value 47.08%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 47.08% | Gross profit / revenue. Period ending 2026-06-30. $87.77M ÷ $186.45M × 100 ≈ 47.08% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 87.77M USD | Gross Profit |
| Revenue | 186.45M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $87.77M | $186.45M | (m) | 47.08% |
| 2026-03-31 | $86.33M | $182.94M | (m) | 47.19% |
| 2025-12-31 | $83.05M | $176.18M | (m) | 47.14% |
| 2025-09-30 | $110.81M | $243.79M | (m) | 45.45% |
| 2025-06-30 | $106.92M | $237.88M | (m) | 44.95% |
| 2025-03-31 | $103.21M | $232.13M | (m) | 44.46% |
| 2024-12-31 | $99.63M | $228.38M | (m) | 43.62% |
| 2024-09-30 | $95.61M | $226.11M | (m) | 42.28% |
| 2024-06-30 | $94.49M | $225.61M | (m) | 41.88% |
| 2024-03-31 | $94.03M | $225.03M | (m) | 41.79% |
| 2023-12-31 | $99.33M | $233.25M | (m) | 42.59% |
| 2023-09-30 | $102.35M | $236.35M | (m) | 43.30% |
| 2023-06-30 | $104.50M | $240.66M | (m) | 43.42% |
| 2023-03-31 | $108.60M | $247.79M | (m) | 43.83% |
| 2022-12-31 | $103.87M | $237.28M | (m) | 43.78% |
| 2022-09-30 | $100.71M | $233.36M | (m) | 43.16% |
| 2022-06-30 | $97.80M | $229.59M | (m) | 42.60% |
| 2022-03-31 | $94.37M | $221.63M | (m) | 42.58% |
| 2021-12-31 | $96.58M | $222.61M | (m) | 43.38% |
| 2021-09-30 | $93.36M | $214.53M | (m) | 43.52% |
| 2021-06-30 | $75.90M | $169.01M | (m) | 44.91% |
| 2021-03-31 | $55.63M | $122.21M | (m) | 45.52% |
| 2020-12-31 | $36.33M | $78.70M | (m) | 46.17% |
| 2020-09-30 | $21.37M | $39.58M | (m) | 54.00% |
| 2020-06-30 | $19.94M | $37.99M | (m) | 52.50% |
| 2020-03-31 | $19.16M | $37.06M | (m) | 51.68% |
| 2019-12-31 | $17.35M | $33.94M | (m) | 51.12% |
| 2019-09-30 | $15.24M | $30.39M | (m) | 50.13% |
| 2019-06-30 | $13.34M | $26.09M | (m) | 51.14% |
| 2019-03-31 | $11.51M | $22.26M | (m) | 51.72% |
| 2018-12-31 | $10.24M | $19.63M | (m) | 52.18% |
| 2018-09-30 | $9.14M | $17.26M | (m) | 52.95% |
| 2018-06-30 | $8.01M | $14.97M | (m) | 53.48% |
| 2018-03-31 | $6.90M | $13.27M | (m) | 52.00% |
| 2017-12-31 | $5.97M | $11.95M | (m) | 49.91% |
| 2017-09-30 | $5.19M | $10.86M | (m) | 47.82% |
| 2017-06-30 | $4.38M | $9.84M | (m) | 44.58% |
| 2017-03-31 | $3.77M | $8.84M | (m) | 42.70% |
| 2016-12-31 | $3.10M | $7.68M | (m) | 40.39% |
| 2016-09-30 | $2.54M | $6.91M | (m) | 36.84% |
| 2016-06-30 | $2.18M | $6.37M | (m) | 34.30% |
| 2016-03-31 | $1.89M | $5.88M | (m) | 32.14% |
| 2015-12-31 | $1.68M | $5.53M | (m) | 30.38% |
| 2015-09-30 | $1.53M | $5.04M | (m) | 30.32% |
| 2015-06-30 | $1.32M | $4.43M | (m) | 29.74% |
| 2015-03-31 | $1.17M | $3.94M | (m) | 29.70% |
| 2014-12-31 | $942.00K | $3.57M | (m) | 26.37% |
| 2014-09-30 | $874.52K | $3.35M | (m) | 26.08% |
| 2014-06-30 | $721.67K | $3.11M | (m) | 23.22% |
| 2014-03-31 | $436.95K | $2.66M | (m) | 16.43% |
| 2013-12-31 | $141.32K | $2.19M | (m) | 6.44% |
| 2013-09-30 | $-87.38K | $1.74M | (m) | -5.01% |
| 2013-06-30 | $-270.32K | $1.40M | (m) | -19.35% |
| 2013-03-31 | $-487.28K | $1.10M | (m) | -44.28% |
| 2012-12-31 | $-487.81K | $908.97K | (m) | -53.67% |
| 2012-09-30 | $-626.62K | $746.07K | (m) | -83.99% |
| 2012-06-30 | $-768.61K | $623.18K | (m) | -123.34% |
| 2012-03-31 | $-836.82K | $555.64K | (m) | -150.61% |
| 2011-12-31 | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | $-827.48K | $475.50K | (m) | -174.02% |
| 2010-12-31 | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |